title: Reply to J. Cabezas et al.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Jessica P
authors.initials: JP
authors.lastname: Hwang
authors.affiliation: American Society of Clinical Oncology, Alexandria, VA guidelines@asco.org.
authors.forename: Mark R
authors.initials: MR
authors.lastname: Somerfield
authors.affiliation: Upstate Oncology Associates, Greenville, SC.
authors.forename: Devena E
authors.initials: DE
authors.lastname: Alston-Johnson
authors.affiliation: Global Liver Institute, Washington, DC.
authors.forename: Donna R
authors.initials: DR
authors.lastname: Cryer
authors.affiliation: Toronto Western Hospital Liver Center, Toronto, Ontario, Canada.
authors.forename: Jordan J
authors.initials: JJ
authors.lastname: Feld
authors.affiliation: National Cancer Institute, Bethesda, MD.
authors.forename: Barnett S
authors.initials: BS
authors.lastname: Kramer
authors.affiliation: Baylor College of Medicine, Houston, TX.
authors.forename: Anita L
authors.initials: AL
authors.lastname: Sabichi
authors.affiliation: University of Michigan, Ann Arbor, MI.
authors.forename: Sandra L
authors.initials: SL
authors.lastname: Wong
authors.affiliation: University of Chicago, Chicago, IL.
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Artz
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018380:Hematopoietic Stem Cell Transplantation; D019694:Hepatitis B, Chronic / Q000175:diagnosis*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D014775:Virus Activation
chemical_list: D000970:Antineoplastic Agents